Most Read Articles
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.
Roshini Claire Anthony, 10 Jan 2020

The rates of ovarian cancer in Singapore have more than doubled over the past 40 years, with evidence of variation between the main ethnic groups, a recent study has shown.

11 Jan 2020
The combination obinutuzumab (Ga101) with the attenuated CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone; miniCHOP) is safe and effective for elderly patients with diffuse large B-cell lymphoma (DLBCL) who are unfit to receive the full-dose immunochemotherapy, a new study has found. However, the new regimen does not seem to be posed to challenge current treatment standards.

Hexavalent vaccines

Prof. Dr. Carl Heinz Wirsing von König
Clinical Microbiologist.
Formerly: HELIOS Klinikum Krefeld, GERMANY
Professor, Heinrich-Heine University
Düsseldorf, GERMANY
17 Dec 2019

Professor Carl Heinz Wirsing von König is a clinical microbiologist and former Director of HELIOS Klinikum Krefeld General Hospital. While currently an independent consultant, he teaches medical students at Heinrich-Heine University Düsseldorf and University of Witten.

Prof von Konig has over 200 publications in peer-reviewed journals and book chapters, as well as over 60 presentations at national and international meetings.

He completed his MD at Universität Düsseldorf in 1974 and completed his habilitation in medical microbiology at Universität Düsseldorf in 1991. He became a professor at Heinrich-Heine-Universität Düsseldorf in 1997.

Prof von König has board certifications in Clinical Pathology, Microbiology, Virology, Infection Epidemiology, Transfusion Medicine and Haemostaseology. He also holds board certifications in Education in Microbiology, Virology and Infection Epidemiology.

He possesses special interest in Bordetella infections and vaccination, and is responsible for the German Reference Laboratory (Konsiliarlabor) for Pertussis.

Professor Carl Heinz Wirsing von König discusses the optimisation of paediatric vaccination with combination vaccines, focusing on vaccine safety and effectiveness.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Singapore digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.
Roshini Claire Anthony, 10 Jan 2020

The rates of ovarian cancer in Singapore have more than doubled over the past 40 years, with evidence of variation between the main ethnic groups, a recent study has shown.

11 Jan 2020
The combination obinutuzumab (Ga101) with the attenuated CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone; miniCHOP) is safe and effective for elderly patients with diffuse large B-cell lymphoma (DLBCL) who are unfit to receive the full-dose immunochemotherapy, a new study has found. However, the new regimen does not seem to be posed to challenge current treatment standards.